The stock of Quest Diagnostics Incorporated (NYSE:DGX) last traded at $154.50, down -0.05% from the previous session.
Data from the available sources indicates that Quest Diagnostics Incorporated (NYSE:DGX) is covered by 18 analysts. The consensus rating among analysts is ‘Overweight’. As we calculate the median target price by taking the range between a high of $173.00 and a low of $125.00, we find $141.50. Given the previous closing price of $154.58, this indicates a potential downside of -8.46 percent. DGX stock price is now 3.65% away from the 50-day moving average and 12.29% away from the 200-day moving average. The market capitalization of the company currently stands at $17.63B.
Will You Miss Out On This Growth Stock Boom?
A new megatrend in the fintech market is well underway. Mobile payments are projected to boom into a massive $12 trillion market by 2028. According to Motley Fool this growth stock could "deliver huge returns." Not only in the immediate future but also over the next decade. Especially since the man behind this company is a serial entrepreneur who has been wildly successful over the years.
And this is just one of our
5 Best Growth Stocks To Own For 2023.
Sponsored
In total, 10 analysts have assigned it a hold rating, and 6 have given it a buy rating. Brokers who have rated the stock have averaged $147.14 as their price target over the next twelve months.
With the price target reduced from $145 to $125, Citigroup Downgraded its rating from Neutral to Sell for Quest Diagnostics Incorporated (NYSE: DGX). , while ‘Citigroup’ rates the stock as ‘Neutral’.
In other news, RING TIMOTHY M, Director sold 2,025 shares of the company’s stock on Dec 01. The stock was sold for $308,812 at an average price of $152.50. Upon completion of the transaction, the Director now directly owns 24,149 shares in the company, valued at $3.73 million. An SEC document containing details of the transaction can be found on the SEC’s website. On Nov 28, SVP, Regional Businesses Doherty Catherine T. sold 40,765 shares of the business’s stock. A total of $6,081,262 was realized by selling the stock at an average price of $149.18. This leaves the insider owning 67,733 shares of the company worth $10.46 million. Insiders disposed of 615,640 shares of company stock worth roughly $95.12 million over the past 1 year. A total of 0.20% of the company’s stock is owned by insiders.
There have been several recent changes in the stakes of large investors in DGX stock. A new stake in Quest Diagnostics Incorporated shares was purchased by GREAT WEST LIFE ASSURANCE CO /CAN/ during the first quarter worth $71,544,000. TUDOR INVESTMENT CORP ET AL invested $10,245,000 in shares of DGX during the first quarter. In the first quarter, JEFFERIES GROUP LLC acquired a new stake in Quest Diagnostics Incorporated valued at approximately $5,759,000. AMALGAMATED FINANCIAL CORP. acquired a new stake in DGX for approximately $5,073,000. ZACKS INVESTMENT MANAGEMENT purchased a new stake in DGX valued at around $4,489,000 in the second quarter. In total, there are 1,232 active investors with 95.00% ownership of the company’s stock.
With an opening price of $153.69 on Thursday morning, Quest Diagnostics Incorporated (NYSE: DGX) set off the trading day. During the past 12 months, Quest Diagnostics Incorporated has had a low of $120.40 and a high of $160.01. As of last week, the company has a debt-to-equity ratio of 0.64, a current ratio of 1.50, and a quick ratio of 1.30. The fifty day moving average price for DGX is $149.36 and a two-hundred day moving average price translates $137.65 for the stock.
The latest earnings results from Quest Diagnostics Incorporated (NYSE: DGX) was released for Sep, 2022. According to the Diagnostics & Research Company, earnings per share came in at $2.36, beating analysts’ expectations of $2.19 by 0.17. This compares to $4.22 EPS in the same period last year. The net profit margin was 11.90% and return on equity was 19.30% for DGX. The company reported revenue of $2.49 billion for the quarter, compared to $2.77 billion a year earlier. Comparatively to last year’s same quarter, the company’s quarterly revenue fell -10.38 percent. For the current quarter, analysts expect DGX to generate $2.25B in revenue.
Moreover, the firm recently paid out its quarterly dividend on 02/01/2023. Investors who held shares on 01/18/2023 were paid a $0.66 dividend. On an annualized basis, this represents a $2.64 dividend and a 1.71% percent yield. There was an ex-dividend date of 01/17/2023 for this dividend. In terms of dividend payout ratio, DGX is presently at 24.60%.
Quest Diagnostics Incorporated(DGX) Company Profile
Quest Diagnostics Incorporated provides diagnostic testing, information, and services in the United States and internationally. The company develops and delivers diagnostic information services, such as routine testing, non-routine and advanced clinical testing, anatomic pathology testing, and other diagnostic information services. It offers diagnostic information services primarily under the Quest Diagnostics brand, as well as under the AmeriPath, Dermpath Diagnostics, ExamOne, and Quanum brands to patients, clinicians, hospitals, independent delivery networks, health plans, employers, direct contract entities, and accountable care organizations through a network of laboratories, patient service centers, phlebotomists in physician offices, call centers and mobile paramedics, nurses, and other health and wellness professionals. The company also provides risk assessment services for the life insurance industry; and healthcare organizations and clinicians robust information technology solutions. Quest Diagnostics Incorporated was founded in 1967 and is headquartered in Secaucus, New Jersey.
